Press Releases

CD Formulation Assists in Solving Dosage Form Development Problems

Clinical Ink Ranked Among Fastest-Growing Companies in North America on the 2021 Deloitte Technology Fast 500™

Clinical Ink today announced it ranked on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 27th year. Clinical Ink grew 293% during this period.

Thermo Fisher Scientific Advances Proteomics Through Select Collaborations and New Analytical Instrument Solutions

Thermo Fisher Scientific has announced a series of co-marketing agreements, in addition to a new chromatography system and acquisition, to support scientists in driving their proteomics research forwards.

Emmes and MedGenome Launch Genomics Strategic Partnership Focused on Advancing Rare Disease Research

Biotium expands multiplexing options for probe-based qPCR with unique red qPCR dye

Biotium has announced the release of EvaRuby™ Dye for qPCR and HRM®.

Vanessa Biotech receives approval from Ghana FDA to proceed with Cholera Phase II Clinical Trial

About Vanessa Biotech Vanessa Biotech (VB) is a biomedical company founded on the desire to “give hope where none existed” by making an impact on healthcare markets often overlooked. Its continually expanding pipeline of innovative pharmaceuticals, medical devices and consumer and public health products reflects the company’s inventive nature and commitment to delivering solutions that increase access to quality care. The company’s flagship product, Shylicine™, is the first-ever drug developed to treat the rare and lethal microvillus inclusion disease. Vanessa Biotech, a University of Connecticut Technology Incubation Program participant, has global offices in Hungary, Spain, and Germany in addition to its Hamden, Conn. corporate campus.

Tesis Labs Announces Name Change to Tesis Biosciences

Tesis Labs Announces Name Change to Tesis Biosciences

CPhI Pharma Index reaches record high as pharma confidence in growth rises in all markets

IBM Research and Arctoris accelerate closed loop drug discovery with AI and Cloud

Today, IBM Research and Arctoris, an Oxford-based technology company operating a fully automated drug discovery platform, announced they are investigating the application of AI and automation to accelerate closed loop molecule discovery.

BioIVT’s Biospecimen Repository and Clinical Database Prove Valuable Resources for AI-Enhanced Drug Discovery and Diagnostic Development

BioIVT’s ASTERAND® Human Tissue Repository contains clinical data from more than one million biospecimens and can be mined to reveal patterns and relationships in disease etiology and pathology.

QualityMetric’s SF-36v2 PRO Survey Contributes to EU’s ORCHESTRA SARS-CoV2 Impact Research

As we continue to navigate the SARS-CoV2 pandemic and new variants of the virus, there is an urgent need to understand how the disease and collective health responses affect the well-being of the general population. QualityMetric’s recent involvement in ORCHESTRA, an ambitious three-year international COVID research project led by the University of Verona. QualityMetric’s SF-36v2® patient-reported outcome (PRO) survey will be used to quantify the disease’s spectrum of symptoms and the functional health and well-being of patients from their own point of view. QualityMetric, a leading global clinical outcomes assessment (COA) solutions provider and scientific consultancy, is building upon our knowledge of the crisis through several COVID impact research initiatives. What makes this newsworthy: • Funded by the EU under the Horizon2020 ERAvsCORONA Action Plan, ORCHESTRA consists of thirty-seven partners from fifteen countries. • The SF-36v2® will help; quantify patient experiences, predict healthcare utilization and evaluate work productivity and job loss to determine COVID’s economic impact. • Researchers are increasingly using PRO measures to clarify the relationship between community disaster events and health-related quality of life. • PRO health surveys help stakeholders forecast health and economic outcomes from advanced predictive algorithms. The SF-36v2® health survey is one of QualityMetric’s most widely used global COA instruments. The data it collects across eight health domains will help the pan-European cohort take an evidence-based approach to developing recommendations for COVID-19 treatment and public health threat preparation.

Rho Named to Top Five Best Places to Work by Triangle Business Journal

CRO recognized among extra-large companies for its culture and flexible work environment during the pandemic Research Triangle Park, NC – September 14, 2021 - Rho, a full-service contract research organization (CRO) with a proven track record of drug development success, has been honored as one of the top five 2021 Best Places to Work for companies with more than 350 employees by the Triangle Business Journal (TBJ), a multimedia source for local business news, research, and events in the Raleigh, Durham, Chapel Hill region of North Carolina, where Rho is headquartered. The Best Places to Work Awards is an annual program recognizing companies for creating policies and a work environment that employees value. The results are presented based upon employee survey feedback conducted by TBJ. Rho has won the award eight times since 2012.

Force Therapeutics Exceeds 110 Clinical Research Studies Published with Leading Medical Journals and Associations

Force Therapeutics Exceeds 110 Clinical Research Studies Published with Leading Medical Journals and Associations

Emmes Standardizes on Veeva Development Cloud to Streamline Product Development

Global CRO builds technology foundation to drive scalability, efficiency, and compliance

Leading Health Systems Adopting the Datavant Switchboard

Datavant has announced a number of health systems, including Geisinger, Emory Healthcare, Bon Secours Mercy Health, and Lee Health, have adopted the Datavant Switchboard of more than 50 million patients’ data , to improve research and patient care.

Elligo Health Research® and ClinEdge Join in Major Expansion

Elligo Health Research, a healthcare-enabling research organization powered by the novel IntElligo® technology, today announced the acquisition of ClinEdge, a research practice management and clinical services organization for clinical research sites, pharma companies, and clinical research organizations.

New Open Wearables Initiative (OWEAR) Program Highlights Emerging De Facto Standards in Open-source Algorithms

OWEAR searchable catalogs will provide a snapshot of, and links to, the published wearables research using open-source algorithms in multiple therapeutic areas.

ZEISS Applies Artificial Intelligence to 3D X-ray Microscope Reconstruction Technologies

ZEISS Applies Artificial Intelligence to 3D X-ray Microscope Reconstruction Technologies Up to 10x higher throughput plus even better image quality with new DeepRecon Pro and PhaseEvolve modules from ZEISS

Xuanzhu and SignalChem Lifesciences Corporation Announce Collaboration and Licensing Agreement for SLC-391 in the Greater China Region

SignalChem Lifesciences has announced that Xuanzhu Biopharmaceutical Co., Ltd. have entered into an exclusive collaboration and licensing agreement for the clinical development and commercialization of SLC-391.

Creative BioMart Provides a Wide Range of Centromere Proteins for Research Use